Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study

Journal of Urology

Volumn 179, Issue 3, 2008, Pages 1066-1071

  Safarinejad, Mohammad Reza ^a   Hosseini, Seyyed Yousof ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

drug therapy; erectile dysfunction; melanocortin; PT 141; receptors; sildenafil

Indexed keywords

BREMELANOTIDE; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PLACEBO; SILDENAFIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; INSOMNIA; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TREATMENT FAILURE;

ADMINISTRATION, INTRANASAL; ADULT; ALPHA-MSH; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, MELANOCORTIN; SULFONES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 39149106751     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.10.063     Document Type: Article

References (20)

1. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., and McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54
2. www.viagramd.com/pi/proPackInsert.asp Accessed September 17, 2003
3. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., and Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338 (1998) 1397
4. Salonia A., Rigatti P., and Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 19 (2003) 241
5. Souverein P.C., Egberts A.C., Meuleman E.J., Urquhart J., and Leufkens H.G. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 14 (2002) 259
6. El-Galley R., Rutland H., Talic R., Keane T., and Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 166 (2001) 927
7. Giuliano F., and Allard J. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug. Int J Impot Res 14 (2002) S53
8. Wessells H., Fuciarelli K., Hansen J., Hadley M.E., Hruby V.J., Dorr R., et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double blind crossover placebo-controlled study. J Urol 160 (1998) 389
9. Wessells H., Gralnek D., Dorr R., Hruby V.J., Hadley M.E., and Levine N. Effect of an alpha melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 56 (2000) 641
10. Molinoff P.B., Shadiack A.M., Earle D., Diamond L.E., and Quon C.Y. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 994 (2003) 96
11. Diamond L.E., Earle D.C., Garcia W.D., and Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 65 (2005) 755
12. Diamond L.E., Earle D.C., Rosen R.C., Willett M.S., and Molinoff P.B. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16 (2004) 51
13. Rosen R.C., Diamond L.E., Earle D.C., Shadiack A.M., and Molinoff P.B. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 16 (2004) 135
14. NIH Consensus Conference: Impotence. NIH Consensus Development Panel on Impotence. JAMA 270 (1993) 83 7
15. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., and Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822
16. Kim S.W., and Paick J.S. Short-term analysis of the effects of as needed use of sertraline at 5 pm for the treatment of premature ejaculation. Urology 54 (1999) 544
17. Fugl-Meyer A.R., Lodnert G., Branholm I.B., and Fugl-Meyer K.S. On life satisfaction in male erectile dysfunction. Int J Impot Res 9 (1997) 141
18. Krane R.J., Goldstein I., and Saenz De Tejada I. Impotence. N Engl J Med 321 (1989) 1648
19. Hadley M.E. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 26 (2005) 1687
20. Safarinejad M.R. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 18 (2004) 205